Abbott Laboratories

NYSE:ABT  
110.33
-1.30 (-1.16%)
Debt Financing / Related, Restructuring / Reorganization, Other Pre-Announcement

Abbott Laboratories Approved A Restructuring Plan

Published: 06/03/2021 22:24 GMT
Abbott Laboratories (ABT) - Abbott Laboratories - Approved a Restructuring Plan.
Abbott Laboratories - Estimates Pre-tax Costs to Be Incurred to Implement Plan to Be Approximately $550 Million to $700 Million.
Abbott Laboratories - Costs Are Expected to Be Incurred During Remainder of 2021 With Majority of Costs Expected to Be Recorded in Q2 of 2021.
Abbott Laboratories - Costs Will Include Fixed Asset Write-downs of $100 Million to $135 Million, Inventory-related Charges of $220 Million to $265 Million.
Abbott Laboratories - Non-cash Charges Included in Total Are Estimated to Be $320 Million to $400 Million.